home > PRODUCTS > TOXINS > Dysport
Dysport
Size: 1x500IU

£ 318.00

RRP: £397.50

OFF: 20%

SKU: B / H / 002

In stock

QTY

减少

增加

DESCRIPTION

    What is Dysport™?

    DYSPORT™ is a prescription medicine injected into muscles predominantly to treat neck pain and the patient's head position which can look abnormal due to cervical dystonia (CD) in adults. It can also be used to treat the look of deep vertical frown lines between the eyebrows which can have a psychological impact on individuals under 65.


    How does DYSPORT™ work in the body and how long will the results last?

    Dysport uses its neurotoxin active ingredient derived from bacteria to inhibit the release of chemicals in the nervous system. This ensures that the corresponding muscles do not receive the chemical messenger which usually makes the muscles begin to contract and spasm.


    CD is caused by muscle spasms in the neck. These spasms cause abnormal position of the head and often neck pain. After DYSPORT™ is injected into muscles, those muscles are weakened for up to 12 to 16 weeks or longer. This may help lessen your symptoms.


    Frown lines (wrinkles) happen because the muscles that control facial expression are used often (muscle tightening over and over). After DYSPORT™ is injected into the muscles that control facial expression, the medicine stops the tightening of these muscles for up to 4 months.


    Note: It is not known whether DYSPORT™ is safe or effective for the treatment of other types of muscle spasms. It is also not known whether DYSPORT™ is safe or effective for the treatment of other wrinkles.


    IMPORTANT SAFETY INFORMATION

    Distant Spread of Toxin Effect: Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses. 


    Dysport is contraindicated in patients with hypersensitivity to any botulinum toxin product or its excipients, including human albumin, lactose, and cow's milk protein, or who have an infection at the proposed injection site. 


    The potency Units of Dysport are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of Dysport cannot be compared to or converted into Units of any other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded.


    Immediate medical attention may be required in cases of respiratory, speech, or swallowing difficulties. Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.


    Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including severe dysphagia and respiratory compromise from typical doses of Dysport. 


    Dysport contains human albumin. Based on effective donor screening and product manufacturing processes, Dysport carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.


    The possibility of an immune reaction when injected intradermally is unknown. The safety of Dysport for the treatment of hyperhidrosis has not been established.


    Patients receiving concomitant treatment of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of botulinum toxin may be potentiated. Use of anticholinergic drugs may potentiate systemic anticholinergic effects. The effect of administering different botulinum neurotoxins during the course of treatment with Dysport is unknown.

Medicine Healthcare Regulatory Agency: Pharmaceutical Wholesale Distribution License No: UK WDA (H) 46138

We accept the following payment methods

@2015- Reliable Medicare RETURNS & REFUNDS PRIVACY POLICY TERMS & CONDITIONS